Mutual recognition or a central European office?
Mutual recognition of marketing authorizations is the solution recommended by the regulatory authorities and pharmaceutical industry in France, for future drug registration in Europe.
The European Federation of Pharmaceutical Industry Associations (EFPIA) has recently provided the European Commission with a policy document.
This document proposes that the two procedures (mutual recogntion or direct access) should work in parallel.
SNIP maintains, in the context of this EFPIA document, that the choice of procedures should be left exclusively to manufacturers.
Regardless of the procedure, authorization should enable free circulation of a medicinal product in all EEC countries, without any obligation on the manufacturer to market in all countries.
KeywordsMedicinal Product Direct Access Marketing Authorization Mutual Recognition Proprietary Medicinal Product
Unable to display preview. Download preview PDF.